Metis Global Partners LLC Sells 2,315 Shares of Eli Lilly and Company $LLY

Metis Global Partners LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.3% during the third quarter, Holdings Channel reports. The institutional investor owned 52,086 shares of the company’s stock after selling 2,315 shares during the quarter. Eli Lilly and Company comprises about 0.9% of Metis Global Partners LLC’s investment portfolio, making the stock its 14th biggest position. Metis Global Partners LLC’s holdings in Eli Lilly and Company were worth $39,742,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Dash Acquisitions Inc. lifted its stake in Eli Lilly and Company by 2.8% during the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after purchasing an additional 13 shares during the period. Nvest Financial LLC lifted its holdings in shares of Eli Lilly and Company by 0.6% during the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock valued at $1,773,000 after acquiring an additional 13 shares during the period. MPS Loria Financial Planners LLC boosted its stake in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock valued at $545,000 after purchasing an additional 13 shares in the last quarter. Key Client Fiduciary Advisors LLC grew its holdings in shares of Eli Lilly and Company by 1.2% in the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after purchasing an additional 13 shares during the last quarter. Finally, Darwin Wealth Management LLC lifted its holdings in Eli Lilly and Company by 3.6% during the 3rd quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock valued at $285,000 after purchasing an additional 13 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.3%

Shares of NYSE LLY opened at $1,038.59 on Friday. The firm’s 50-day moving average is $1,051.78 and its 200-day moving average is $904.70. The firm has a market capitalization of $981.86 billion, a PE ratio of 45.25, a price-to-earnings-growth ratio of 1.18 and a beta of 0.39. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The firm’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 26.14%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Robust fundamentals and guidance — Lilly reported a strong Q4 beat and raised FY2026 outlook, underscoring surging GLP‑1/weight‑loss revenue and underpinning investor optimism. How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report
• Positive Sentiment: Pre‑launch inventory build — Lilly filed that it has about $1.5 billion of pre‑launch inventory for its experimental oral weight‑loss pill, signaling management confidence in commercialization and readiness to capture market share if approved. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Positive Sentiment: M&A to expand pipeline — Lilly agreed to acquire Orna Therapeutics for up to $2.4B, adding an RNA platform that diversifies growth beyond GLP‑1s and supports longer‑term R&D optionality. Eli Lilly to acquire ‘world’s most innovative biotech startup’ for up to $2.4B
• Positive Sentiment: Analyst upgrades & institutional buying — recent upgrades (Freedom Capital to strong‑buy) and a stake increase by Fisher Asset Management reinforce buy‑side conviction. Zacks / analyst coverage
• Neutral Sentiment: Industry tailwinds from AI and biotech momentum — broader analyst pieces highlight AI drug‑discovery and biotech sector strength that could benefit Lilly longer term, but these are thematic rather than company‑specific catalysts. 2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
• Neutral Sentiment: Market commentary and price forecasts — multiple outlets publish bullish multi‑year forecasts and “reasons to buy” writeups; useful for sentiment but speculative for near‑term price moves. Stock Price Prediction and Forecast 2026-2030
• Negative Sentiment: Regulatory binary risk — the April FDA decision on the oral weight‑loss pill is binary and could trigger significant volatility; the large pre‑launch build increases both upside on approval and downside on rejection or delays. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Negative Sentiment: Competitive dynamics — Novo Nordisk remains a dominant competitor in obesity drugs; market‑share battles, pricing pressure or faster rival launches could blunt Lilly’s growth trajectory. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market

Analyst Ratings Changes

Several analysts have weighed in on LLY shares. Rothschild & Co Redburn upped their price objective on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research note on Monday, January 26th. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a report on Thursday, February 5th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Finally, Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,217.71.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.